According to Zacks, “Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company’s product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States. “
Several other research firms have also issued reports on IKNA. HC Wainwright raised their target price on shares of Ikena Oncology from $25.00 to $26.00 and gave the stock a buy rating in a report on Wednesday, April 13th. Credit Suisse Group lowered their target price on shares of Ikena Oncology from $27.00 to $24.00 in a report on Thursday, March 17th.
Ikena Oncology (NASDAQ:IKNA – Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.05). On average, equities research analysts forecast that Ikena Oncology will post -1.87 earnings per share for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc lifted its holdings in Ikena Oncology by 143.9% during the 4th quarter. Legal & General Group Plc now owns 2,273 shares of the company’s stock valued at $29,000 after buying an additional 1,341 shares in the last quarter. Morgan Stanley raised its holdings in shares of Ikena Oncology by 787.6% in the 3rd quarter. Morgan Stanley now owns 3,231 shares of the company’s stock valued at $41,000 after purchasing an additional 2,867 shares in the last quarter. Baystate Wealth Management LLC bought a new stake in shares of Ikena Oncology in the 4th quarter valued at about $38,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Ikena Oncology by 5.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 66,810 shares of the company’s stock valued at $408,000 after purchasing an additional 3,276 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Ikena Oncology by 25.4% in the 1st quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock valued at $104,000 after purchasing an additional 3,482 shares in the last quarter. Institutional investors own 67.33% of the company’s stock.
Ikena Oncology Company Profile (Get Rating)
Ikena Oncology, Inc, a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
- Get a free copy of the StockNews.com research report on Ikena Oncology (IKNA)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.